journal article·2019-12-04Open access

P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

Niloofar Farzad, Nastaran Barati, Amir Abbas Momtazi-Borojeni, Mona Yazdani, Atefeh Arab, Atefeh Razazan, Sheida Shariat, Mercedeh Mansourian, Azam Abbasi, Zahra Saberi, Ali Badiee, Seyed Amir Jalali, Mahmoud Reza Jaafari

Abstract

The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Science

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences

Nanotechnology Research Center, Department of Medical Biotechnology, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences

Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences

Funding

Biotechnology Research Center and Nanotechnology Research Center, Mashhad University of Medical Sciences

References (62)

Show source-provided references
1. 10.1016/j.ejphar.2009.09.06710.1016/j.ejphar.2009.09.067 ↗
2. 10.1126/science.342.6165.143210.1126/science.342.6165.1432 ↗
3. Wei Y. The influence of calcium infiltration on the sintering behavior and dissolution of beta-tricalcium phosphate [Master thesis]. University of Pittsburgh; 2015.
4. 10.1111/j.1749-6632.1999.tb09401.x10.1111/j.1749-6632.1999.tb09401.x ↗
5. 10.1016/S1074-7613(00)00026-110.1016/S1074-7613(00)00026-1 ↗
6. 10.1093/intimm/dxg07810.1093/intimm/dxg078 ↗
7. 10.1016/S0140-6736(00)04904-710.1016/S0140-6736(00)04904-7 ↗
8. 10.1016/j.coi.2007.12.00210.1016/j.coi.2007.12.002 ↗
9. 10.1016/S0264-410X(01)00326-710.1016/S0264-410X(01)00326-7 ↗
10. 10.1016/S0167-4889(01)00182-310.1016/S0167-4889(01)00182-3 ↗
11. Krieg A, Davis H. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Therap. 2001;3:15–24.
12. 10.2174/18722081179636571610.2174/187220811796365716 ↗
13. 10.1016/j.vaccine.2012.01.07010.1016/j.vaccine.2012.01.070 ↗
14. 10.1016/0022-1759(91)90120-510.1016/0022-1759(91)90120-5 ↗
15. 10.1002/jcp.2636110.1002/jcp.26361 ↗
16. 10.1517/1742524090301886310.1517/17425240903018863 ↗
17. 10.1007/978-1-4615-1823-5_2110.1007/978-1-4615-1823-5_21 ↗
18. 10.1016/S0171-2985(11)80355-410.1016/S0171-2985(11)80355-4 ↗
19. 10.1007/s00018-008-8228-610.1007/s00018-008-8228-6 ↗
20. 10.4161/onci.2093110.4161/onci.20931 ↗
21. 10.1146/annurev-immunol-032414-11224010.1146/annurev-immunol-032414-112240 ↗
22. 10.1159/00005539610.1159/000055396 ↗
23. 10.1007/s00262-005-0692-310.1007/s00262-005-0692-3 ↗
24. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16–20.
25. 10.1016/j.canlet.2014.09.01610.1016/j.canlet.2014.09.016 ↗
26. 10.1016/j.imlet.2014.07.00810.1016/j.imlet.2014.07.008 ↗
27. 10.2174/156720181366616071216414910.2174/1567201813666160712164149 ↗
28. 10.1016/j.imlet.2016.05.01610.1016/j.imlet.2016.05.016 ↗
29. 10.1016/j.nano.2011.09.01010.1016/j.nano.2011.09.010 ↗
30. 10.1038/3258810.1038/32588 ↗
31. 10.1146/annurev.immunol.18.1.76710.1146/annurev.immunol.18.1.767 ↗
32. 10.1016/0014-5793(94)00351-310.1016/0014-5793(94)00351-3 ↗
33. 10.1023/A:101211753144810.1023/A:1012117531448 ↗
34. 10.1023/A:101108121014210.1023/A:1011081210142 ↗
35. 10.1016/j.biomaterials.2005.05.08210.1016/j.biomaterials.2005.05.082 ↗
36. 10.1021/mp300190g10.1021/mp300190g ↗
37. 10.1038/pj.2016.3110.1038/pj.2016.31 ↗
38. 10.1016/S0264-410X(02)00103-210.1016/S0264-410X(02)00103-2 ↗
39. 10.1016/j.vaccine.2004.09.00210.1016/j.vaccine.2004.09.002 ↗
40. Shariat S, Badiee A, Jaafari MR, et al. Optimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancer. Iran J Pharm Res. 2014;13:15–25.
41. 10.1038/nprot.2006.410.1038/nprot.2006.4 ↗
42. 10.1016/S0021-9258(18)70226-310.1016/S0021-9258(18)70226-3 ↗
43. 10.1006/abio.1997.221610.1006/abio.1997.2216 ↗
44. 10.1016/j.nano.2017.08.01010.1016/j.nano.2017.08.010 ↗
45. 10.1016/0022-1759(94)90110-410.1016/0022-1759(94)90110-4 ↗
46. 10.1007/0-387-24180-9_1210.1007/0-387-24180-9_12 ↗
47. 10.1016/0022-1759(91)90142-310.1016/0022-1759(91)90142-3 ↗
48. 10.1016/j.vaccine.2013.04.02710.1016/j.vaccine.2013.04.027 ↗
49. 10.1371/journal.pone.014256310.1371/journal.pone.0142563 ↗
50. 10.1016/0008-8749(80)90165-310.1016/0008-8749(80)90165-3 ↗
51. Raphael L, Tom B. Liposome facilitated xenogeneic approach for studying human colon cancer immunity: carrier and adjuvant effect of liposomes. Clin Exp Immunol. 1984;55:1.
52. 10.1016/j.actatropica.2013.07.02110.1016/j.actatropica.2013.07.021 ↗
53. 10.1016/j.imlet.2017.07.00910.1016/j.imlet.2017.07.009 ↗
54. 10.1084/jem.175.2.60910.1084/jem.175.2.609 ↗
55. 10.1016/S0264-410X(01)00104-910.1016/S0264-410X(01)00104-9 ↗
56. 10.1006/viro.1997.892210.1006/viro.1997.8922 ↗
57. 10.1016/S0006-3495(97)78336-X10.1016/S0006-3495(97)78336-X ↗
58. 10.1073/pnas.81.6.171510.1073/pnas.81.6.1715 ↗
59. 10.1021/bi00334a00410.1021/bi00334a004 ↗
60. 10.1016/S1359-6446(03)02864-210.1016/S1359-6446(03)02864-2 ↗
61. 10.1038/nri286810.1038/nri2868 ↗
62. 10.1016/j.exppara.2012.09.00110.1016/j.exppara.2012.09.001 ↗